COVID-19

Studies tie disease to higher risk of COVID-related hospitalizations and deaths

The latest guidance for when to administer the COVID-19 vaccine to patients aged 6 months and older.

Adults aged 18 and older are eligible to receive the vaccine.

Groups responded quickly in defense of pharmacists’ ability to prescribe Paxlovid through Test to Treat programs.

The risk of breakthrough was higher in people living with HIV regardless of CD4 count or HIV viral suppression, according to findings reported by researchers at Johns Hopkins.

According to the agency, this new authority may improve access to patients at high risk for severe COVID-19.

Purchase follows FDA recommendation to include Omicron component in boosters.

Epic research suggests that like COVID-19, flu and other viral pneumonias can result in long-term symptoms like fatigue and brain fog. Why that might be is open question.

Recent research has shown less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19.

Monoclonal antibodies have been helpful in preventing severe illness in patients at increased risk, but barriers to receiving this therapy exist.

A majority of survey respondents were willing to receive a COVID-19 vaccine.

Staying abreast of current data on the condition is vital.

If authorized, it will be the fourth COVID-19 vaccine available in the Untied States.

Results address the concern that COVID-19 vaccination might not be effective among those living with HIV.

Research suggests that COVID-19 vaccination may serve a therapeutic effect, possibly reducing the risk of developing long COVID when administered to those currently infected.

Communities who are undeserved and vulnerable to COVID-19 were found to be not have much-needed access to test-to-treat location, according to an analysis by the American Pharmacists Association.

The test will be available direct to consumers without a prescription.

Children may receive a single booster shot at least 5 months after completing their initial Pfizer-BioNTech 2-dose series.

A comparison of COVID-19 PCR tests and rapid self-tests found self-tests to be highly accurate and user-friendly for children.

COVID-19 updates and news to know as of May 16, 2022.

A session at the 40th Annual Meeting of the European Society for Pediatric Infectious Diseases looks at how the pandemic impacted the used of antimicrobials.

Investigators examined whether rapid antigen tests were less sensitive to variants of concern. Though the tests detected Omicron, all but 1 were less effective in detecting the Delta variant.

The administration also pledged to continue its work with existing pharmacy partners to improve the patient experience.

The country's COVID-19 death toll is nearing 1 million.

Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children.

Respondents to a recent poll were still hesitant to get the Pfizer-BioNTech shot.

Data from COVID-19 vaccine distribution could spark improvements for future vaccination efforts.

A recent study evaluated 4 million Tweets published in 2021.

There are no easy solutions for people who gained insurance coverage through Medicaid.

The amended authorizations apply to the Pfizer-BioNTech and Moderna COVID-19 vaccines.